CPRX
Big pharma, meet America
Catalyst Pharmaceuticals is officially off the dating apps. Angelini Pharma has agreed to buy the company for $31.50 per share in cash, valuing the deal at about $4.1 billion and implying a 28% premium to Catalyst’s 30-day average price as of April 22.
For Angelini, this is less “let’s grab lunch” and more “we’d like the keys to the U.S. market, please.” The Italian pharma company says the deal deepens its focus on brain health and rare disease while giving it a much bigger footprint stateside. That’s the strategic version of buying a house instead of continuing to rent.
What investors should care about
If you own CPRX, the headline here is pretty simple: the company is being acquired for cash, so the market now has to price in deal completion, not future growth dreams. That usually means:
- the stock tends to hover near the deal price unless something gets weird
- the main risk becomes closing risk, not quarterly execution
- any upside from here is mostly about whether the transaction finishes on time
The long wait begins
The boards already approved the transaction, and closing is expected in the third quarter of 2026. Between now and then, investors will be watching for the usual deal drama: approvals, paperwork, and whether the clock actually says Q3 when the confetti falls.
Big picture: Catalyst’s standalone chapter is winding down, and Angelini is buying its way into a bigger U.S. story in one very expensive move.